Moqi Liu, Xueqiao Jiao, Rui Li, Jialu Li, Lu Wang, Liyan Wang, Yishu Wang, Chunmei Lv, Dan Huang, Ran Wei, Liming Wang, Xunming Ji, Xiuhai Guo
BACKGROUND: We aimed to determine whether and how the combination of acetazolamide and remote ischemic preconditioning (RIPC) reduced the incidence and severity of acute mountain sickness (AMS). METHODS: This is a prospective, randomized, open-label, blinded endpoint (PROBE) study involving 250 healthy volunteers. Participants were randomized (1:1:1:1:1) to following five groups: Ripc (RIPC twice daily, 6 days), Rapid-Ripc (RIPC four times daily, 3 days), Acetazolamide (twice daily, 2 days), Combined (Acetazolamide plus Rapid-Ripc), and Control group...
January 2, 2024: BMC Medicine